<DOC>
	<DOCNO>NCT01399359</DOCNO>
	<brief_summary>RATIONALE : Learning patient make decision use chemoprevention may help doctor plan treatment patient willing choose chemoprevention reduce breast cancer risk . PURPOSE : This clinical trial study factor influence decision-making use chemoprevention woman increase risk breast cancer .</brief_summary>
	<brief_title>Factors Influencing Decision-Making About Use Chemoprevention Women Increased Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To describe influence social , environmental , psychological factor ( sociality medication intake , life-events , understand prevention , clinical situation ) decision woman risk breast cancer whether take chemoprevention agent . Secondary - To determine implication influence decision-making diagnosis `` risk breast cancer '' woman . - To determine factor hind woman take chemoprevention breast cancer . - To field test questionnaire identifies factor influence decision-making process woman increase risk breast cancer chemoprevention medically indicate option . - To describe influence social , environmental , psychological factor decision woman risk breast cancer whether take chemoprevention agent menopausal status . - For postmenopausal woman decide take selective estrogen-receptor modulator ( SERM ) breast cancer prevention , assess reason choice raloxifene versus tamoxifen . OUTLINE : This multicenter study . Participants undergo counsel session increase risk breast cancer use selective estrogen-receptor modulator ( SERM ) , tamoxifen citrate raloxifene , reduce breast cancer risk . Some participant may counsel session video-recorded . They also ask review video interviewer contact brief follow-up telephone interview . Participants complete initial questionnaire ass recall understand risk information give counsel session . This first questionnaire complete preferably day counsel leave clinic office . Participants also option take questionnaire home return study site within 2 week . Participants return first questionnaire complete second one leave clinic office , receive mail return self-addressed stamp envelope . Participants indicate second questionnaire want take SERM ask complete online questionnaire . Participants make decision SERM use within 3 month counsel contact telephone . They also receive second questionnaire mail 3 month telephone contact . Interviewers , doctor , health-care professional also complete questionnaire indicate discuss counseling session .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion The participant must female . The participant must great equal 35 year age . The participant must Englishspeaking . The participant must identify increase risk breast cancer determine doctor/healthcare professional ( HCP ) . ( Increased risk breast cancer base Gail score . ) During participant 's counseling session , breast cancer risk use SERMs breast cancer risk reduction must discuss , report doctor/HCP conduct session . Note : This criterion apply participant ask counsel session participate video record component DMP1 select NSABP site . Exclusion criterion Previous invasive breast cancer type . Previous history ductal carcinoma situ ( DCIS ) . Previous history lobular carcinoma situ ( LCIS ) treat mastectomy , radiation therapy , endocrine therapy . Participation cancer prevention study involve pharmacologic intervention ( ) osteoporosis prevention study involve pharmacologic intervention ( ) . Any history current tamoxifen , raloxifene , SERM therapy reason . ( Participants eligible SERM use discuss prior counsel session long SERMs never use . )</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>breast cancer</keyword>
</DOC>